Introduction

ABSTRACT
The efficacy of cancer immunotherapy is limited because of central and peripheral immune tolerance towards tumor-antigens. We propose a novel approach based on the fact that the immune system has not evolved tolerance towards adenoviruses (Ads) and that Ads have not evolved efficient mechanisms for immune-escape. The host-response to intratumoral Ad-vector injection in mice that were immunologi cally tolerant to neu-positive syngeneic mammary-cancer (MMC) was investigated. Intratumoral injection with replication-deficient, transgene-devoid Ad induced immune responses at two different anatomical sites: the tumor-draining lymph nodes and the tumor microenvironment. The lymph nodes supported the generation of both neu-and Ad-specific T effector cells, while inside the tumor microenvironment only Ad-specific T cells expanded. Importantly, Ad-specific T cells were anti-tumor-reactive despite the presence of active regulatory T cell-mediated immune tolerance inside MMC tumors and anti-tumor efficacy of Ad was increased by pre-immunization against Ad despite the production of Ad-neutralizing antibodies.
Adenovirus (Ad) serotype 5 based vectors have been developed as therapeutics for cancer in the recent decade and are the most frequently used viral gene vectors in clinical trials [1] . Ads have naturally evolved to efficiently infect a wide variety of cells, rapidly complete their life cycle (viral genome replication, viral protein expression, progeny viral particle assembly) and lyse the host cell within this process. Accordingly, one therapeutic strategy has been to restrict Ad-replication to tumor cells ("oncolysis") [2] . As a differ ent approach, injection with El-deleted, replication-deficient Ads has been used to express various therapeutic transgenes in tumors.
In clinical trials Ad-vectors have been generally safe. When sys temically applied, Ad-vectors have not had significant anti-tumor efficacy. This has been, in part, attributed to cellular and non cellular blood components that efficiently bind Ads and sequester it in particular to the liver and spleen upon application into the blood stream [3.4] . In contrast, when Ads are directly injected into tially directed towards conserved Ad-epitopes within the Ad-capsid (mostly Ad-hexon protein) and kill infected cells (using multiple mechanisms that include perforin. Fas-L and TNFOl). which disrupt the Ad life cycle before progeny viruses are assembled. Ad-specific antibodies are frequently targeted against the serotype-specific ("hypervariable") Ad-epitopes that are located on the surface ofthe viral particle and circulate through the periphery to functionally neutralize Ads [15.16] .
In contrast to an inhibitory function. Ad-triggered immune responses could also synergize with anti-tumor effects. e.g. because replication of the virus could be involved in releasing tumor specific antigens to dendritic cells and innate and adaptive immune responses triggered by adenoviruses could create a pro inflammatory environment inside the tumor that could facilitate the activation of tumor-antigen-specific T cells. thereby triggering not only anti-virus but also anti-tumor immunity. This hypothesis is under investigation for a variety of viral vectors. including aden ovirus vectors. and being tested in pre-clinical models and clinical trials [17.18] .
To investigate immunological responses to Ad-vector-mediated cancer therapy one needs an immunocompetent syngeneic model that allows Ad-infection and Ad-replication. Since human Ads rarely replicate in non-human cells few such models are available. including Syrian hamsters. cotton rats. mice and canines [19] [20] [21] [22] and it was not investigated in any of these models whether the Ad-induced immune response itself could have a function in anti tumor efficacy. This is the first study to systematically investigate immune responses towards both Ad-vector-and tumor-antigens in immunocompetent animals. Towards this goal we characterized a novel syngeneic in vivo model. We found that mouse mammary carcinomas (MMC) in neu-transgenic mice supported Ad-infection and Ad-replication in vivo. Similar to human breast cancers. MMC tumors induced neu-specific T effector cells in the sentinel lymph nodes (LN). Surprisingly. we found that the dominant anti-tumor mechanism of intra tumoral Ad-vector injection was the induction of Ad-specific. and not neu-specific. T effector responses.
Materials and methods
Mice and cells
Neu-transgenic (neu-tg) mice [strain name: FVB/N Tg(MMlVneu )202Mul] were obtained from theJackson Laboratory (Bar Harbor. ME). These mice harbor non-mutated. non-activated rat neu under control ofthe mouse mammary tumor virus (MMlV) promoter. The neu transgene is expressed at low levels in normal mammary epithelium. salivary gland. and lung. Until the age of 8 month -35% of female neu-tg mice spontaneously develop mam mary carcinomas that display high neu-expression levels. ens specific for the immunodominant H-2Dq/RNEU420-429 epitope can be detected in neu-tg mice using the corresponding tetramer [23] . Mouse mammary carcinoma (MMC) cells were established from a spontaneous tumor in a neu-tg mouse. MMC cells have been shown to display high levels of neu-expression. an epithelial phenotype. expression ofMHC class I and II and presentation ofthe immunodominant neu-epitope H-2Dq/RNEU420-429 [24] . Culture conditions for MMC cells were RPMI-l640 medium containing 10% fetal bovine serum (FBS). 2mM L-glutamine (GIn). 100U/ml penicillin (P). and 100 ""g/ml streptomycin (S). Immunodejident (SCID) mice [strain name: NOD.CB17-Prkdc scid /J] were obtained from the Jackson Laboratory. These mice are homozygous for the severe combined immune deficiency spontaneous mutation (Prkdcsd d a.k.a. SCID). which is mainly characterized by an absence of functional T cells and B cells. lymphopenia. hypogammaglobu linemia. and a normal hematopoietic microenvironment. Human cancer cell lines: Human lung epithelial cancer cells (A549) and human embryonic kidney derived cells (293) were both obtained from the ATCC (Manassas. Virginia) and cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS. GIn/PIS. 293 cells express the human Ad5-El genes and were used for propagation of El-deleted Ad-vectors and pfu-assays (see below).
Adenovirus vectors
All vectors were based on Ad serotype 5 and had the E1A and E1B genes (nucleotides 342-3523) and the E3 genes (nucleotides 28.133-30.818) deleted (with the exception of Hl0l; see below). The structure of all vectors is shown in Suppl. Fig. 2 . Ad.zero is a control vector that lacks a transgene. Ad.GFP and Ad.lacZ are vec tors that express the corresponding reporter genes. Ad.IR-GFP and Ad.IR-IacZ express the reporter genes in a replication-dependent manner. Ad.OlCD3 and Ad.OlCD137 express membrane bound forms of mouse monoclonal antiCD3 and antiCD137 scFv. respectively. Ad.IL-15 and Ad.UGHT express the secreted mouse cytokines IL lS and UGHT. respectively. Ad.IR-E1A/AP expresses the adenoviral E1A protein and human alkaline phosphatase in a replication dependent manner. Ad.IR-E1A/TRA1L expresses the adenoviral E1A protein and human TRAIL in a replication-dependent manner.
Recombinant viruses were propagated in 293 cells. banded in eso gradients. dialyzed and stored in aliquots as described [25] . To assess contamination of AdEl-vector preparations with El+ replication-competent adenovirus (RCA). real-time PCR quan tification for AdEl+ genomes was performed [10] . Only virus preparations that contained less than one El + (RCA) viral genome in 1 x 109 genomes were used. Ad-particle (viral particle. VP) concen trations were determined spectrophotometrically by measuring the optical density at 260nm (OD260)' Plaque titering (plaque forming units. pfu) was performed using 293 cells as described elsewhere [25] . The pfu:VP ratios for all Ad preps were -1 :20. Multiplici ties of infection (MOls) in this study were stated as pfu per cell (pfu/cell) for all assays. Endotoxin contamination was tested with an Endotoxin detection kit (BioWhittaker. Walkerville. MD). All vec tors were free of endotoxin.
Real-time PCR
Real-time PCR was performed using a tightCycler (Roche) and the QuantiTect™ Sybr® Green PCR Kit (Qjagen). For transcript analy sis total RNA from samples was extracted using the RNeasy Mini Kit (Qjagen). RNA was reverse transcribed and genomic DNA was removed using the QuantiTect Reverse Transcription Kit (Qiagen). For DNA analysis total DNA from samples was extracted and RNA removed using the Blood and Cell Culture DNA Mini Kit (Qiagen). Conditions for real-time PCR were 15 min at 95' C followed by 50 amplification cycles (20 s at 60°(, 20s at 72 °C and 15 s at 95 =C). Primer pairs for amplification are listed in Tab. S1. Specificity of amplification products was confirmed using melting curve analy sis and agarose gel electrophoresis. Positive samples were used to generate standard curves. Transcript/DNA levels were presented as fold increase. Transcript/DNA input was normalized using i3-actin control primer.
Flow cytometry
Flow cytometry was performed using a BD FACScalibur (BD Bio sciences. San Diego. CA). Samples were pre-treated with Fc-block (anti-CD16/CD32. BD Biosciences) for 15 min. stained for 30 min on ice in washing buffer (W8; PBS-l%FBS) and washed three times with WB. mc-or PE-conjugated isotype-controls were included in all experiments. Anti-E-cadherin-PE antibody (clone 114420. R&D Systems. Minneapolis. MN) was used to detect MMC cells. For flow-cytometry analysis ofimmune cells the following monoclonal antibodies (mAbs) were used: anti-FoxP3-PE (clone FHK16s; cells were permeabilized according to the manufacturer's instruction; eBioscience), anti-CD4-FITC (clone RM4-5), anti-CD8-FITC (clone 53-6.7), anti-NKl.l-PE (clone PK136), anti-CD80 (clone 16-lOA1), anti-CD86 (clone GLl) (all from BD Biosciences). The PE-labeled H-2Dq/RNEU420_429 (H-2D(q)PDSLRDLSVF) tetramer was obtained from the National Institute of Allergy and Infectious Diseases MHC Tetramer Core Facility (Atlanta, GA) and used according to the man ufacturer's instructions.
Lymphocyte enrichment
In order to enrich speCifically for lymphocytes, samples (spleens, inguinal lymph nodes, tumors) were minced and filtered through a 70-j.l.m cell strainer (BD Biosciences). Spleen suspensions were additionally treated with BD PharmLyse (1:10 dilution; BD Biosciences) for 1 min at RT and washed twice in WB. Tumor infiltrating lymphocytes (TIL) were separated from tumor cells and erythrocytes by centrifugation of the tumor cell suspension on a Ficoll gradient (Histoplaque 1083, Sigma). For this cell suspensions were layered onto the top ofthe gradient in a 15-ml Falcon tube fol lowed by centrifugation at 800 x g for 50 min at RTwithout braking. Lymphocytes were collected and washed twice in WB.
Isolation ofintratumoral cells
To generate viable single-cell suspensions of MMC tumors that contained all intratumoral cell fractions (in particular MMC, immune and stroma cells) for flow-cytometry analYSis, tumors were minced into small pieces and then immersed in 5 ml diges tion mixture (RPMI-1640 with 10% fetal bovine serum, 50 j.l.l of 1 % collagenase, and 50 j.l.l of 1 % DNase (both from Life Technologies, Carlsbad, CA)). This mixture was incubated in a water bath at 37°C for 2h and mixed by pipetting every 20 min. 5ml Versene (Gibco) was then added and the mixture was incubated in a water bath at 37°C for another 1 h, mixed by pipetting every 20 min, and then filtered through a 70-j.l.m screen followed by washing twice in WB.
EUspot
For quantification of Ad-specific T cells, splenocytes of naive neu-tg mice were ex vivo pulsed with Ad.zero (MOl 50 pfu/cell) as described before [26) . Lymphocytes from spleen, LN, and tumor were harvested and 1 x 10 6 cells (spleen, LN) or 2.5 x 10 5 cells (TIL) were mixed with 1 x 10 6 ex vivo pulsed splenocytes for in vitro sensitization. After 24 h of incubation in 96-well plates, cells were plated in anti-IFN-)l-coated wells of Ells pot plates (Millipore, Bedford, MA). 24 h later, plates were washed and the spots of lFN )I-producing T cells were counted.
Immunohistochemistry/immunohistof/uorescence
MMC cells were cultured in Lab-Tek 8-well chamber glass slides (Nalge Nunc International, Rochester, NY). MMC tumors were cryofixed in ocr compound (Miles, Elkhart, Ind.) and Cry omolds (Tissue-Tek, Torrance, CA), cut with a cryostat in 8j.1.m sections that were transferred to glass slides. LacZ: For detection of lacZ expression slides were fixed with a solution containing PBS, 0.5% glutaraldehyde, and 1 mM MgCh (0.5% glutaraldehyde PBS) for 20min at room temperature (RT) and incubated with 5-bromo-4-chloro-3-indolyl-~-D-galactopyranoside (X-Gal). Reac tion was stopped by washing with PBS. Slides were mounted with Vecta Mount Medium (Vector Laboratories, Burlingame, CA). AP: For detection of AP expression, slides were fixed using 0.5% glutaraldehyde-PBS for 30 min at RT. After the samples were washed with PBS, they were incubated at 65'C for 1 h to inactivate endogenous AP. Staining was performed in a solution containing 0.1 M Tris (pH 9.5), 0.1 M NaO, 0.5 mg of NBT (4-nitroblue tetra zolium chloride) (Roche Diagnostics) permiIlilitre, and 0.1875 mg of BCIP (5-bromo-4-chloro-3-indolylphosphate) (Roche Diagnostics) per miIIilitre. Reaction was stopped by washing with PBS. Slides were mounted with Vecta Mount Medium (Vector Laboratories).
Antibodies: Slides were fixed with acetone/methanol (10min) and washed twice with PBS. Slides were blocked for 20 min at RT using PBS-5% blotting grade milk (B10-RAD, Hercules, CA) followed by incubation with primary antibodies in PBS for 1 hat RT. Then slides were washed twice with PBS and incubated with secondary anti bodies for 1 hat RT followed by washing with PBS three times. Slides were washed twice with PBS, mounted with Mounting Medium for Fluorescence (Vector Laboratories) and then analyzed using a fluorescence microscope. Laminin was detected using anti-Iaminin polyclonal (primary) antibody (1 :200; #Z0097; Dako, Carpinteria, CA) and goat anti-rabbit-IgG AlexaFluor568 (secondary) antibody 
Cytotoxidty assays
Cells that were incubated with Ad-vectors and/or lymphocytes were continuously monitored for signs of cytotoxicity. Cytotoxicity was defined as the presence of both a discontinuous cellular mono layer ("gaps") and detached ("round") cells at the same time. For crystal violet staining cells were washed with PBS and fixed with 4% paraformaldehyde for 5 min at RT. Fixed cells were washed with PBS and incubated for 3 min in 1 % crystal violet in 70% ethanol, followed by three rinses with water. Air-dried cells were photographed.
Ad-neutralizing antibodies
100 j.l.l of blood was extracted from immunized and non immunized mice using retro-orbital eye bleeding followed by centrifugation of samples at room temperature and collection ofthe supernatant. Serum samples were stored at -80°C. For determin ing the titer of neutralizing antibodies, serial (1 :2) serum dilutions were generated for each sample, AdS weight was added for 1 h at RT to each dilution and samples were applied to 293 cells, which were monitored for CPE for 7 days.
Animal experiments
Neu-tg and SCID mice were bred under specific pathogen free conditions at the University of Washington (Seattle, WA). Animal care and use was in accordance with institutional guide lines. Female mice at the age of 6-10 weeks were used for all experiments. Tumor cell transplantation: MMC cells were harvested using Versene (Gibco) and washed in RPMI-1640 medium (without supplements) before injection. Mice received anesthesia (Avertin i.p.) and were injected with 5 x 10 5 MMC cells (diluted in 100j.l.I RPMI-1640 without supplements) subcutaneously on the right mid-dorsum with a 23-gauge needle. Tumors were measured every other day and tumor volume was calculated as the product of length x width x width. For survival studies tumor sizes :::500mm 3 were considered the experimental endpoint. Animals with tumor sizes :::500mm 3 For some experiments injection of each antibody was repeated every 3 days to main tain the depletion. Anti-mouse CD4 and anti-mouse CD8 antibodies were produced in SCID mice. purified from ascites using standard protein G column purification. dialyzed against PBS and stored at -80°C. Depletion efficacy of antibodies was tested in neu-tg mice (Fig. 510) . Ad-immunjzation: For establishing pre-existing anti-Ad immunity 2.5 x 10 9 pfu Ad.zero was injected intramuscularly (in lOO!Jo1 PBS) or intraperitoneal (in 500!Joi PBS). A second injection was performed 14 days later using 1 x 10 9 pfu. 
Statistical analysis
Results
Ad-vectors
In this study the following 12 vectors divided into four categories were tested (see Section 2 and 
30)). IL-15 (activates T effector but not regulatory T cells via IL-15R receptor [31)) and LIGHT (activates T and NK cells via multiple receptors [32]). (D)
Oncolytic vectors: Towards the goal ofincreasing anti-tumor efficacy via tumor-specific viral replication the following oncolytic vectors were included: HI0l (a.k.a. ONYX-015) has been the most com mon oncolytic vector in clinical trials [5] [6] [7] [8] . Ad.IR-EIA/TRAIL has been developed in our laboratory and shown to express EIA and pro-apoptotic TRAIL in a strictly replication-dependent manner in cancer cells [33] .
Ad-vectors induce replication-and immune-mediated cytotoxicity in MMC cells in vitro
Since mouse cancer cells rarely support both infection and repli cation of human Ads. we first tested syngeneic mouse cell lines for their susceptibility towards human Ads. For this purpose we utilized Ad-vectors that expressed GFP independent (Ad.GFP) or dependent (Ad.IR-GFP) on viral genome replication [9.10] . Mouse mammary-cancer cells (MMC; derived from syngeneic tumor antigen neu-transgenic mice (23)) supported Ad-mediated GFP expression which was dependent and independent of Ad-vector replication (Fig. lA) . This was confirmed by using hydroxyurea to inhibit adenoviral replication [10] which impaired GFP expression via Ad.IR-GFP but not via Ad.GFP (Fig. lA) . Ad.IR-GFP-mediated GFP expression was more than 100-times less as compared to Ad.GFP-mediated expression of this transgene. This indicated that replication-independent transgene expression was more efficient than replication-dependent transgene expression. We further con firmed that MMC cells supported Ad.IR-mediated expression of other transgenes including lacZ and alkaline phosphatase (AP) using Ad.lR-lacZ and Ad.IR-EIA/AP. respectively (data not shown).
Next we looked for adenoviral proteins that are naturally expressed during adenoviral replication. To do this we chose the Ad-hexon protein since it is an abundant component in the adenovi ral capsid and typically over-expressed at a late stage of adenoviral replication. We compared two vectors that were either replication competent (Ad.IR-E1A(fRAlL) or replication-deficient (Ad.zero). Using immunofluorescence. nuclear expression of Ad-hexon pro tein was detected only for Ad.lR-EIA(fRAIL-infected but not for Ad.zero-infected MMC cells. indicating that only Ad.IR-EIA(fRAIL vector replicated (Fig. IB) . However. we have previously shown that human cancer cells also support low-level background repli cation of E1/E3-deleted replication-deficient Ads (although this usually does not induce CPE; [9.10)). Therefore we further investi gated Ad.zero and Ad.lR-EIA/TRAIL replication in MMC cells using highly sensitive real-time RT PCR for the detection of EIA (early replication-stage transcript) and hexon mRNA (late replication stage transcript). Ad.lR-E1A/TRAIL-infected but not (El/E3-deleted) Ad.zero-infected MMC cells showed EIA transcripts expression (Fig. 1C ). However. hexon mRNA was detectable in both Ad.zero and Ad.lR-EIA/TRAIL infected cells. Notably. hexon transcript levels in Ad.zero infected MMC cells were more than 100-fold lower. Next. we tested whether MMC cells supported the amplification of viral genomes and the production of progeny infectious viral particles (plaque forming units; pfu). comparing vectors that were either replication-competent (Ad.lR-EIA(fRAIL) or replication-deficient (Ad.zero). For Ad.lR-EIA/TRAIL we detected a ~4-fold increase of genome levels 5 days post infection which indicated genomic replication. although this was less efficient than in human A549 cells. where a ~58-fold increase of genome levels was detected ( . In contrast to replication-competent Ad.lR-EIA/TRAIL. for replication-deficient Ad.zero no significant Ad-genome or Ad-pfu production was mea surable in both MMC and human A549 cells ( Fig. 10. right We next tested whether MMC cells supported the Ad incorporation; Fig. 2E ) of splenocytes and the resulting cytotoxicity vector mediated expression of the following immunoadjuvants:
towards MMC cells (CPE; Fig. 2F, 2G ) was tested. With the exception aCD3scFv, aCD137scFv, LIGHT or IL-15 (Fig. 52) . The first ofAd.aCD3, all other Ad-vectors only minimally increased the IFN two immunoadjuvants are membrane-bound scFvs ( [27] [28] [29] [30] and ' Y secretion and splenocyte proliferation when compared to Ad.zero Fig. 53 ). Surface expression of aCD3scFv and aCD137scFv was or mock-infection ( Fig. 2D and E) and this did not induce cytotox detected in vector-transduced MMC cells using antibody stain icity towards MMC cells (Fig. 2F ). In contrast, Ad.aCD3 mediated a ing ( Fig. 2A) and expression of IL-15 and LIGHT by testing the strong increase of splenocyte activation (~8-fold increase of IFN culture supernatants from vector-transduced MMC cells by ELISA ' Y secretion; Fig. 2D ), vigorous splenocyte proliferation (~lO-fold ( Fig. 28 and C) . In conclusion, all vectors efficiently expressed increase of 3 H-incorporation; Fig. 2E ) and importantly, splenocyte their immunoadjuvant in MMC cells. Next, the functionality of mediated cell death in 100% of MMC cells ( Fig. 2F and G) . Notably, the expressed immunoadjuvants was assessed using standard CD3-activation with an agonistic anti-CD3scFv bypasses T cell immunoassays. Towards this goal, non-transduced and vector receptor activation and is routinely used for antigen-unspecific in transduced MMC cells were incubated with splenocytes of naIve vitro expansion ofT cells. The observed lymphocyte activation and syngeneic neu-tg mice at different effector:target (E:T) ratios. Acti MMC cell killing by membrane-bound anti-CD3scFv in this assay vation (IFN-'Y secretion; Fig. 2D ) and proliferation eH-thymidine was therefore most likely in an antigen-non-specific manner. MMC cells (cultured in T cell medium) were infected with Ad-vectors (MOl 100 pfu/cell). 24 h later fresh syngeneic splenocytes (from naive neu-tg mice) were added (E:T ratio 100) and incubated for 2 days. Splenocytes were harvested and IFN-oy secretion was quantified via EUspot assay. For the proliferation assay ljLCi was added for 16h and 3H-thymidine incorporation was quantified using a scintillation counter. In summary, the data showed that syngeneic mouse MMC cells provide a novel model for testing human Ad5-based vectors. MMC cells supported Ad-vector infection and Ad-vector-mediated trans gene expression. Furthermore, replication-competent Ad-vectors showed efficient expression of viral proteins, genomic replication and CPE induction in MMC cells, although de-novo production of infectious progeny viral particles was not supported. Finally, we identified several vectors that showed enhanced anti-tumor activ ity: Ad.lR-EIA/TRAIL and H101 were the most efficient vectors for replication-dependent MMC cell lysis, and Ad.nCD3 was the most efficient vector for triggering lymphocyte-mediated killing ofMMC cells in vitro.
MMC tumors support Ad-vector transduction and
We therefore tested the functionality of Ad-vectors in vivo.
Towards this goal, MMC cells were subcutaneously injected into syngeneic immunocompetent neu-tg mice, where they formed vascularized tumors that maintained an epithelial phenotype (E-cadherin surface expression) with cell clusters that were surrounded by extracellular matrix (Iaminin; Fig. 55 ). Various lym phoid cells infiltrated the MMC tumors, in particular CD4+FoxP3+ T cells (regulatory T cells), CD4+FoxP3-(T helper cells), CD8+ T cells and NK cells (Fig. 56) .
To functionally evaluate Ads we injected them directly into MMC tumors. First, replication of Ad-vectors was tested. Replication competent Ad.IR-EIA/TRAIL but not replication-deficient Ad.zero induced positive hexon staining 3 days after vector injection (Fig. 3A) . This was in agreement with our in vitro data (Fig. 1) . How ever, hexon staining was not detectable 7 days after vector injection (not shown). This indicated that vector replication is only present at early time points in vivo. We confirmed that MMC tumors sup ported Ad-vector replication using replication-dependent reporter gene expression with Ad.IR-based vectors that strictly express their reporter transgenes in a replication-dependent manner [10] . For Ad.IR-lacZ and Ad.IR-EIA/AP we again detected reporter gene expression 3 days post infection (Figs. 3B, 57 ) but not 7 days after injection (not shown). For Ad.IR-EIA/AP-injected tumors we found that positive AP staining co-localized with positive hexon stain ing, indicating co-expression of the reporter protein (AP) and viral protein (hexon) in vivo (Fig. 57) . Finally, at day 7 post-injection no Ad-vector genomes, nor EIA mRNA expression were detectable in tumors by qPCR analyses. This indicates that Ad-transduced tumor cells are cleared by a CTL response within 7 days.
Having discovered that Ad-vector replication occurs at early time points (within less than 7 days post infection) in MMC tumors, we evaluated vectors that expressed their transgenes inde pendently of viral replication. Overall, replication-independent expression was more efficient than replication-dependent trans gene expression (compare lacZ expression via Ad.IacZ and Ad.IR-lacZ. Fig. 3B ). This observation was in agreement with our in vitro data (compare Ad.GFP and Ad.IR-GFP; Fig. 1A ).
Next, immunoadjuvant-expressing vectors (Ad.cxCD3/nCD137/IL IS/LIGHT) were tested. In vivo expression of the respective immunoadjuvant transgenes was confirmed using qRT-PCR 48 h post intratumoral vector injection (data not shown). In the case of IL-15 we did detect that this cytokine was already expressed inside the tumor prior to injection of the vector and that infec tion with Ad.IL-15, but not with Ad.zero, increased IL-15 transcript levels (-3.6-fold, Fig. 58) .
Next, the transduction efficacy with replication-deficient Ad vectors was evaluated more quantitatively using flow cytometry. For this purpose MMC tumors were injected with Ad.GFP. Tumors were harvested 24 h later and single-cell suspensions were gen erated and analyzed via flow cytometry for GFP reporter gene expression and E-cadherin as a surface marker for MMC cells. The in vivo transduction rate was -32% of cells inside the tumor (Fig. 3C) . Importantly, both MMC cells (E-cadherin high) and non MMC cells (E-cadherin low) were transduced with equal efficacy inside the tumor (Fig. 3C) . Using mean GFP fluorescence intensity as a quantitative marker for MMC cell transduction, the average mul tiplicity of infection (MOl) was determined as -35 pfu/cell in vivo (Fig. 59) . Finally, we assessed intratumoral apoptosis using TUNEL staining 5 days post infection (Fig. 3D) . A replication-deficient Ad vector (Ad.zero) was compared against a replication-competent Ad-vector (Ad.IR-EIA/TRAIL). Seven days after vector injection, sig nificantly increased numbers of apoptotic cells were detectable in both Ad.zero and Ad.IR-EIA/TRAIL injected MMC tumors (these differences were less pronounced 3 days after injection; data not shown). This was surprising considering the fact that no vector replication was detectable at this time point. Apoptotic cells were also found in untreated tumors, indicating spontaneous apoptosis. The overall conclusion of the TUNEL staining was, however, lim ited since we found that only -50% of the intratumoral cells were MMC cells (Fig. 3C ) and the TUNEL assay did not indicate whether neoplastic or stroma cells were apoptotic in vivo.
Together the data showed that MMC tumors allowed for Ad-replication and Ad-mediated trans gene expression in an immunocompetent setting in vivo, although Ad-replication was limited to less than 7 days post intratumoral injection.
In vivo efficacy ofAd-vectors against MMC tumors depends on Tcells
To investigate the role ofthe immune system in the anti-tumor efficacy ofAd-vectors we established MMC tumors subcutaneously in syngeneic immunocompetent (neu-tg) and immunodeficient (SCID) mice. Similarly to neu-tg mice, 5CID mice supported the formation of vascularized MMC tumors with similar intratumoral architecture (epithelial phenotype, extracellular matrix, nodule structure; Fig. 55 ). The median survival ofMMC tumor-bearing mice was 14 days for both neu-tg and SCID mice, indicating that MMC tumors grow equally well in both mouse strains.
We first tested the anti-tumor efficacy of replication-competent vectors (HI0l, Ad.IR-EIAfTRAIL) compared to replication-deficient vectors (Ad.lacZ, Ad.zero; Fig. 4A ). In SCID mice none of these vec tors significantly increased median survival (MS) for more than 1.5 days. In contrast, all vectors significantly increased median survival in neu-tg mice for at least 5 days. These data strongly suggested that Ad-mediated anti-tumor efficacy was dependent on a functional immune system in vivo (compare SCID versus neu-tg mice; Fig.4A ).
Additionally, together with the fact that MMC cells supported repli cation of these vectors in vivo (Figs. 3, 57) , the data indicated that although Ad-replication increased anti-tumor efficiency in vitro (Figs. 1. 54) , it was not an important component for anti-tumor activity in vivo (compare Ad.zero versus Ad.IR-EIA/TRAIL and HI0l; Fig. 1 versus Fig. 4A ). The vector with the best anti-tumor efficacy in neu-tg mice was Ad.lacZ (median survival: 23 days, maximum survival: 32 days; Fig. 4A ), which significantly increased survival compared to all other vectors (e.g. compare Ad.zero and Ad.lacZ; Fig. 4A ). The fact that lacZ expression increased Ad-mediated anti tumor efficacy only in neu-tg but not in SCID mice indicated that it (A) Ad.zero I.t.
Ad.lR-E1A1TRA1L t.t. .., was also dependent on the immune system. Our findings were not expected from the previous in vitro data. which had indicated better efficacy for replication-competent H101 and Ad.lR-E1AfTRAIL than for replication-deficient Ad.zero and Ad.lacZ (Figs. 1. $4). Since our data indicated that immunological mechanisms were responsible for the anti-tumor effect of Ad-vectors we next tested immunoadjuvant-expressing vectors in vivo. Ad.nCD3. Ad.nCD137.
Ad.lL-15 and Ad.UGHT were compared to Ad.zero in neu-tg mice (Fig. 4B) . None of these immunoadjuvant-expressing vectors were more anti-tumor efficient as compared to Ad.zero and Ad.nCD3 (which had shown the best immunostimulatory efficacy in vitro; (transgene-devoid) Ad-vector (Ad.zero) showed therapeutic effects that were dependent on a functional immune system. Based on these findings a series of subsequently experiments were per formed exclusively using Ad.zero and Ad.lacZ in immunocompetent neu-tg mice. To investigate which lymphoid cells were responsible for the Ad Most humans develop CD4+ and CD8+ T cell-dependent anti-Ad vector-mediated anti-tumor effects we depleted CD4+ and CD8+ T immunity early in life [11 I . It was therefore next tested whether cells and NK cells over the entire period of tumor growth and treat pre-existing adaptive immunity against Ads would interfere with ment. Efficacy of lymphocyte-depleting antibodies was confirmed T cell-mediated anti-tumor effects of Ad-vectors. For this pur via flow cytometry (Fig. SlO) . In short, depletion ofCD8+ and CD4+ pose. naIve neu-tg mice were immunized via intramuscular or T cells but not depletion ofNK cells inhibited the Ad-mediated anti intraperitoneal Ad.zero injection (day 0, day 14) and tested for the tumor efficacy, as indicated by significantly shorter median survival titers of neutralizing anti-Ad antibodies (day 28). Both routes of times (Fig. 4C) . This indicated that CD4+ and CD8+ T cell-mediated immunization significantly increased titers of neutralizing anti-Ad immune responses were an essential component of Ad-mediated antibodies (Fig. 511) into the tumor (Fig. 40) . Surprisingly. we observed an increased anti-tumor efficacy of Ad.zero in Ad-immunized animals as indi cated by significantly increased median survival times (Fig. 40) . Considering this result. we hypothesized that the Ad-specific T cell-mediated response could be a component of Ad-mediated anti-tumor efficacy. Therefore we assessed whether the frequency of T cells with Ad-antigen specificity would change in tumor infiltrating lymphocytes (TIL), sentinel lymph nodes or spleen 10 days after intratumoral Ad-injection. Importantly, we found that intratumoral Ad-injection significantly increased the number of Ad reactive T cells in all tested lymphocyte compartments (Fig. 4E) . The increase was -2.4-fold for TIL. -3.7-fold for splenocytes and -4.2-fold for sentinel LN, respectively. This indicated that intratu moral Ad.zero injection triggered the expansion and/or infiltration of anti-Ad T cells inside both the lymphoid organs and the tumors. We hypothesized that one possible mechanism by which anti Ad T cells could inhibit MMC tumor growth would be direct cell killing of Ad-transduced cells, considering that (a) crLs are a nat ural component of the anti-adenoviral immune response during natural Ad-infection [11, 15, 16] . (b) MMC cells can present anti gens via major histocompatibility complex (MHC) class I and II [23.24] , (c) Ad.zero showed Ad-hexon background expression in MMC cells (Fig. 1C) , which is generally considered to favor MHC class I epitope presentation of viral proteins [34] . In order to test whether Ad-transduced MMC cells were preferentially eradicated by the immune system in vivo we next injected Ad.IacZ into MMC tumors that were established in SCID (immunodeficient) or neu tg (immunocompetent) mice. Tumors were harvested at different days post injection and lacZ transgene expression was quantified using real-time RT PCR (Fig. 4F) . In both types of mice a continu ous decrease of lacZ expression was detectable over time. However, lacZ expression was overall significantly decreased in neu-tg mice as compared to SCID mice. On day 2 and 4 post injection, intra tumoral lacZ transcript levels were -4-fold lower in neu-tg mice. Importantly, on day 8 post injection lacZ expression was detectable only in SCID mice but not in neu-tg mice. This result indicated that Ad.IacZ transduced MMC cells had a significantly shorter life span in immunocompetent mice compared to immunodeficient mice. Overall, the data suggested that the anti-tumor efficacy of intratumoral Ad-injection was dependent on immune responses mediated by C04+ and C08+ T cell but not NK cells. Ad-specific T effector cells appeared to be an important component of this response, since (a) T effector cells with Ad-specificity expanded inside the tumor microenvironment and lymphoid organs (Fig. 4E) , (b) Pre-existing anti-Ad immunity increased therapeutic efficacy of Ad-injection (Fig. 40) and (c) Ad-transduction shortened the life span of transduced MMC cells in immunocompetent ani mals (Fig. 4F) . Immunoadjuvant-expression and Ad-replication both failed to enhance anti-tumor efficacy in vivo (Fig. 4A and B ), although these strategies had shown anti-tumor efficacy in vitro (Figs. 1 and 2) . Notably, Ad-mediated laCZ reporter gene expression increased immune-mediated therapeutic efficacy in vivo (Fig. 4A) We therefore tested the effect of intratumoral Ad-injection on but not in vitro (Figs. 2. 54) .
(a) the tumor microenvironment (primary site of infection). (b) the tumor-draining (sentinel) lymph nodes and (c) the spleen. Spleen and LN were both investigated since antigens can either 3.5. In vivo T cell responses inside the tumors, tumor-draining be transported with the blood stream or with the lymphatic lymph nodes and spleen from mice with Ad-transduced MMC system (passively or actively by migrating APCs). The follow tumors ing studies were focused exclusively on Ad.zero since this vector allowed us to determine the effect of the Ad-vector system Immune responses to antigens (e.g. adenoviral-or tumor itself. associated antigens) are generally generated in secondary lymphoid organs (lymph node or spleen) from which activated immune cells spread into the periphery (e.g. to other lymphoid organs.
Tumor microenvironment the infection-and/or tumor-sites). Lymphoid organs provide
First. immune responses in the microenvironment of Ad optimal conditions (in particular for antigen-presentation and co infected tumors were investigated. We focused exclusively on C04+ stimulation via antigen presenting cell [APCs)) for Tcell expansion.
and C08+ T cells. since our previous data showed that they were essential and sufficient for Ad-mediated anti-tumor efficacy in vivo (Fig. 4C) . In previous studies anti-Ad T cell responses peaked approximately one week post intravenous administration in mice [3sJ. We therefore harvested tumors 8 days post intratumoral Ad.zero (or mock) injection. Tumors were weighted. then tumor infiltrating lymphocytes (TIL) extracted. counted. and analYzed via flow cytometry (Fig. 5) .
Tcell responses in untreated tumors
We determined the percentage of CD4+ and C08+ T cells in TIL using flow cytometry (Fig. SC) . In order to specifically measure C08+ Tcells that were reactive towards the immunodominantneu420_429 epitope. the corresponding tetramer was used (see Fig. SC and Section 2). In order to distinguish C04+ T helper from C04+ T regula tory cells (Tregs) intracellular staining for FoxP3 was used (Fig. SC) . FoxP3 is a sensitive and specific marker for Tregs. since FoxP3 expression is essential for the function of Tregs and not present in T helper cells [36J. Surprisingly. we found that the majority of T cells in the TIL of untreated tumors were CD4+ T cells (-12% of TIL). whereas C08+ T cells were only a minor T cell fraction ( -2% of TIL). Infiltration ofT cells into the MMC tumor microenvironment was confirmed using immunohistochemistry (Fig. S6) . Interest ingly. -38% of intratumoral CD4+ T cells were FoxP3+ (Fig. sC) . which was in stark contrast to other lymphocyte compartments. In particular. in the spleen (Fig. S12) and LN (Fig. 60) only -9% of C04+ T cells were FoxP3+. Overall the ratio of C08+ T cells towards Tregs was lower in TIL (-0.7) as compared to LN (~s. 5) or spleen (~4). This indicated a reversed effector/suppressor T cell ratio inside untreated MMC tumors (in particular an abundance of C04+FoxP3+ Tregs over CD4+ T helper cells and CTLs). Interestingly. -12% of intratumoral C08+ T cells were specific for the immun odominant neU420-429 epitope (Fig. SC) . This was again different from the peripheral lymphoid organs: in the spleen (Fig. S12) and LN (Fig. 60) only -0.3 and -0.7% of C08+ T cells were specific for the neu420-429 epitope (neu+). respectively. Overall. the data indi cated that untreated MMC tumors were selectively enriched for both regulatory T cells and neu+ C08+ T cells. Surprisingly. the nat ural attraction of neu-specific CTLs into the tumor was apparently not sufficient to suppress tumor growth. which was also indicated by the fact that MMC cells formed tumors in immunocompetent neu-tg mice. C08+ T cell-depleted neu-tg mice and SCID mice with equal efficacy (Fig. 4A and C) .
Ad-induced Tcell responses
The tumor weight was significantly decreased in Ad.zero injected tumors. whereas the total number of TIL/mg tumor was significantly increased as shown in Fig. SA and B . Using flow cytom etrywe observed a strong increase oftumor-infiltrating C08+ Tcells (from -2% to ~24% of TIL; Fig. SC ). This significantly increased the C08/Treg ratio from -0.7 to -7.4 (the latter ratio was compara ble to lymphoid organs; see Figs. 60. S12). However. the number of neu+ CTLs did not increase in TIL (Fig. SC) . As a result. the per centage of neu-specificity in the C08+ T cell population actually decreased significantly (from -12% to -2%; Fig. 50 ). This indicated that Ad-injection induced infiltration of C08+ T cells into the tumor microenvironment that were specific for antigens others than neu. Furthermore. we observed that Ad-injection led to an increase of C04+FoxP3-T cells inside the tumor whereas the number of intra tumoral Tregs (CD4+FoxP3+) remained unchanged (Fig. 50) . This significantly decreased the percentage ofFoxP3+ cells in C04+ T cells from -38% to -20% and indicated that incoming C04+ T cells had an effector and not a suppressor phenotype (Fig. SC) . Correspond ing to these data. quantification of IFN-j' and TGF-j3 expression at this time point also showed a -167% increase for IFN-j' and -19% decrease of TGF-j31 transcript levels. although these differences did not reach statistical significance (Fig. S13) . IFN-j' is a hallmark cytokine for C04+ Th1 cells. whereas TGF-j31 has been shown to mediate immunosuppressive functions ofCD4+FoxP3+ Tregs [37J.
Tumor-draining lymph nodes
We next investigated T cell responses inside the lymph nodes (Fig. 6) and spleen (Fig. 512) . Spleen. sentinel LN (R. right flank) and non-sentinel LN (l., left flank) were harvested from animals 6 days post intratumoral Ad.zero (or mock) injection. Spleens and LN were weighted. lymphocytes extracted and total lymphocyte numbers per spleen/LN determined and f1ow-cytometry analysis was used to determine the percentage of different T cell populations.
Tcell responses in untreated mice
MMC tumors naturally triggered an increase in LN weight and the number of lymphocytes in the sentinel LN but not in the non-sentinel LN or spleen (Figs. 6B and C. S12). According to f1ow cytometry analysis the percentage ofCD4+FoxP3-/+ and neu-/+C08+ T cells was the same in the sentinel and non-sentinel LN (Fig. 60) . However. due to the increased total number of lymphocytes in the sentinel LN (Fig. 6C) . both types ofT cells increased there (Fig. 6E) . i.e. MMC tumors triggered a T cell response in the sentinel LN that included the induction and expansion of both immunosuppressive (C04+FoxP3+) and tumor-specific T effector cells (neu+C08+ Tcells). This was not observed inside the non-sentinel LN or spleen (Figs. 6E. S12).
Ad-induced Tcell responses
The weight and cell number of the sentinel LN was further increased by intratumoral Ad-injection ( Fig. 6B and C) . while there was no change of the weight or cell number of the spleen or non sentinel LN; Figs. 6B and C. S12). The percentage of C04+FoxP3-/+ and neu-/+C08+ T cells in the sentinel LN remained constant (Fig. 60) . butthe total number ofall T cell sub-populations increased (Fig. 6E) . Therefore. we conclude that intratumoral Ad-injection had an immunoadjuvant effect on the induction of C04+FoxP3-/+ and neu-/+C08+ T cells inside the tumor-draining LN (Fig. 6B-E) .
Overall. intra tumoral Ad-injection induced T cell responses mainly in tumors and sentinel LN. In the tumor-draining LN both neu-specific (Fig. 6E ) and Ad-specific T cells (Fig. 4E) increased sig nificantly. indicating the simultaneous expansion there of T cell clones specific for both antigens. In contrast. in the tumors there was only an increase of T effector cells with Ad-specificity in response to in situ Ad vaccination (Figs. 4E. SO).
Oiscussion
Immunosuppression in the tumor microenvironment. primarily mediated by regulatory T cells (Tregs). prevents the generation of an immune response to tumor-associated self-antigen(s). One way to circumvent this problem is to localize to the tumor a strong non self-antigen to which there is no tolerance. In this study we esta blish a rationale for a T cell-mediated cancer immunotherapy based on the facts that adenoviruses have not evolved efficient mechanisms to establish immune tolerance and that the immune system has evolved to effiCiently recognize Ads as strong immunogens and to trigger Ad-specific T cell responses that are not suppressed by peripheral tolerance mechanisms. in particular Tregs.
There is an emerging picture that the same mechanisms that prevent autoimmunity also inhibit anti-tumor immune responses. The central problem in cancer immunotherapy is that most tumor associated antigens (e.g. neu) are non-mutated self-antigens that have triggered both central and peripheral tolerance. Central toler ance is established by selection in the thymus: T cells bearing T cell receptors (TCRs) with high affinity for self-antigen are eliminated through apoptosis [38) . Additionally. peripheral T cell tolerance is required to suppress the remaining auto-reactive T cells in the periphery. Recent studies showed that, besides myeloid-derived suppressor cells and immature dendritic cells, a specialized sub set of regulatory T cells (Tregs) is pivotal for maintaining peripheral immune tolerance [36] . Nevertheless, we and others have shown that neu-specific T effector cell immunity can be triggered sponta neously or vaccine-induced in ovarian and breast cancer patients, but this anti-tumor immunity has mostly failed to show clinical benefi ts [39, 40] . There is accumulating evidence tha t multiple types of cancers, including ovarian and breast cancer, actively recruit and induce Tregs inside their microenvironment for the purpose of locally suppressing CfLs with tumor-antigen specificity [36, 41, 42) .
MMC tumors in neu-tg mice spontaneously triggered neu specific T effector cells inside the sentinel lymph nodes (Fig. 6) , which poorly infiltrated tumors and were functionally inactive in the tumor microenvironment (Figs. 4 and 5 ) and these findings are consistent with the previous observation from patients with breast or ovarian cancer [39] [40] [41] [42] . We have previously shown in neu-tg mice that depletion of regulatory T cells enabled activation and clonal expansion of neu-specific C08+ T cells in vivo, which subsequently mediated MMC tumor regression [23] . Together with the findings of this study that MMC tumors selectively enriched neu-specific C08+ and regulatory T cells inside the tumor microen vironment ( (Fig. 3) . This, together with the possibility to quantify both anti-Ad and anti-neu responses, allowed us to analyze the role of the immune system in Ad-vector-mediated anti-tumor efficacy in a comprehensive manner. We showed that one injection of MMC tumors with Ad (1 x 10 9 pfu) resulted in the transduction of -32% of cells inside the tumor microenvironment ( Fig. 3C ) with an average MOl of -35 pfulcell (Fig. 59) . Replication of vectors was limited to less than 7 days in neu-tg mice (Fig. 3) . Ad-transduction was also transient (less than 8 days) in neu-tg mice but significantly longer in 5CID mice (Fig. 4F) , which indicated an immune response towards Ad-transduced cells. We conclude that immune responses limited the efficacy of Ads as gene transfer vectors and Ad-vector injection would be required at least every 8 days to induce continuous expression of a transgene inside MMC tumors.
The main conclusion from our study is that in situ injection with replication-deficient, transgene-devoid Ad-particles was capable of inducing immune responses that inhibited tumor growth (Fig. 4) . We show that the main effector-components ofAd-mediated anti tumor efficacy were C04+ and C08+ T cells (Fig. 4C) . The majority of Ad-triggered T effector cells were specific for Ad-antigens but not for the tumor-antigen neu and only T cells with Ad-specificity expanded inside the tumor microenvironment (Fig. 4E, Fig. 50 ). Importantly, Ad-triggered T effector cells were functionally active despite the presence of intratumoral Treg-mediated immune tol erance that subdued neu-specific CTLs [23] . Ads were readily recognized as pathogens in neu-tg mice as indicated by induction ofAPC maturation (Fig. 514) , (ii) Ad-specificT cells (Fig. 4E ) and (iii) Ad-neutralizing antibodies (Fig. 511) upon Ad-administration. We conclude that Ad-derived antigens were "foreign" and apparently not protected by central or peripheral (Treg-mediated) immune tol erance in neu-tg mice and Treg depletion was therefore not required to enable the anti-Ad immune response. In contrast, tumor associated antigen neu was a "self'-antigen and Treg-depletion has been shown to be required to enable an efficient anti-neu response in neu-tg mice [23] . The dominance ofthe adaptive anti-Ad immune response was not predicted by in vitro experiments (Fig. 2) and was only present in vivo (Figs. 4-6 ), most likely because clonal expansion of Ad-specific T cells was only supported in the in vivo setting. Importantly, Ad-mediated anti-tumor efficacy was further enhanced by pre-existing anti-Ad immunity (Fig. 40) .
We identified factors that enhanced, inhibited and did not influ ence the therapeutic efficacy of Ad-vectors in vitro and in vivo. Overall we observed that efficacy screenings of Ad-vectors in vitro or in 5CID mice did not predict the mechanism or the anti-tumor efficacy of Ad-vectors in immunocompetent syngeneic mice.
Ad-replication
Replication-competent Ads (HI01, Ad.lR-EIA/TRAlL) were more anti-tumor effective than EI/E3-deleted replication-deficient Ad.zero in vitro (Figs. I, 54) but not in vivo (Fig. 4A) . Ad-replication was only detectable at early time point (less than 7 days post injection; Fig. 3) and not an important effector mechanism in vivo (Fig. 4A) . We speculate that the discrepancy between the in vitro and in vivo findings had multiple reasons: (a) In vitro, 100% of cells were transduced (Fig. 1) , while in vivo the transduction rate was -32% (Fig. 3C): (b) de-novo production of infectious viral particles was not supported by MMC cells in vitro (Fig. I ) and in vivo (Fig. 3) ; (c) Most importantly, Ad-replication was not required to induce anti Ad responses in vivo (Fig. 4) and in agreement to this, other studies also previously found that innate and adaptive anti-Ad responses were independent of viral replication [12, [43] [44] [45] .
Pre-existing anti-Ad immunity
This is, to our knowledge, the first study to show that pre existing immunity against Ads was a favorable factor for an effective anti-tumor response (Fig. 40) . A large majority of individuals in the human population develop adaptive anti-Ad immunity against wild-type Ad early in life [11] . Hence, we propose that a high pro portion of the human population would be pre-conditioned for the proposed immunotherapy approach. Neutralizing antibodies (Fig. 510) did not interfere with Ad-mediated anti-tumor efficacy upon intratumoral Ad-application (Fig. 40) .
NK cells
NK cells were apparently not an effector component of Ad vector-mediated anti-tumor activity (Fig. 4C) . Expression of Ad El and E3 genes during natural Ad-infection has been proposed to render host cells susceptible to NK cell-mediated eradication (46) . However, the vectors used in this study were EI/E3-deleted and NK cell-inhibitory molecules (e.g. MHC complex I and II) were expressed on MMC cells [241, which both might have contributed to the fact that Ad-infected MMC cells were not susceptible to NK cells. Notably, HI01 was only partly EI/E3-deleted and therefore NK cells might have played an active role in immune-mediated responses towards cells infected by this vector.
Immunoadjuvant expression
None of the tested immunoadjuvants (anti-C03scFv, anti C0137scFv, IL-15, LIGHT) enhanced the immunotherapeutic potential of Ads in vivo (Fig. 4B) . This was surprising since especially anti-C03scFv expression greatly enhanced the immuno genicity of MMC cells in vitro (Fig. 2) . We speculate that the abundance of Tregs inside MMC tumors might have con tributed to diminishing the therapeutic effect of anti-C03scFv, since Tregs express C03 and CD3-activation could potentially further enhance the immunosuppressive functions of these cells. The lack of co-stimulatory molecules (C080 or C086) on MMC tumors, which have been shown to be important for the anti-tumor activity of membrane-anchored anti-C03 scFv, may have also contributed to poor therapeutic efficacy [28] . For anti-C0137scFv, we have previously shown that NK cells represent a main effector arm for immune-mediated anti tumor effects with this immunoadjuvants [29, 30) . The fact that NK cells naturally did not have a major effector func tion against MMC cells (Fig. 4C) and that MMC cells naturally expressed NK cell inhibitors [24) might have contributed to the inefficacy of anti-C0137scFv in this model. Additionally, we have previously shown that, in particular in tumors that pre-dominantly utilize active immune-tolerance mechanisms, tumor-localized antibody-mediated immunotherapy (e.g. using anti-C0137scFv or anti-CTIA-4 antibody expression) was more effective when combined with interference of the function of immunosuppressive cells (e.g. using low-dose cyclophosphamide) [30, 47) .
LaCZ reporter gene expression
LacZ unexpectedly increased the immunotherapeutic effect of Ads (Fig. 4A) . We speculate that the increased in vivo effect of Ad.lacZ is due to the fact that lacZ (similarly to Ad antigens) is not a self-antigen and therefore not protected by immune tolerance. LacZ is derived from E. coli and there are only minor amino-acid homologies to the corresponding murine and human enzymes (Fig. SIS) . Previous studies showed that the lacZ protein contained multiple epitopes that were pre sented via MHC class I and triggered lacZ-specific crL responses [48, 49) . We show in this study that this could be used to increase therapeutic immune response against cancer. Ad.lacZ also provided a proof-of-principle that expression of a transgene can be used to increase the immunotherapeutic potentials of Ads.
While MMC cells have the capability of antigen-presentation [23, 24) , many cancers lack this capability as a result of "immunoediting" [50) . In extensively "immunoedited" cancers other Ad-therapy components (in particular oncolysis, transgene expression and/or NK cell responses) could therefore be dominant as compared to the T cell-mediated anti-Ad response. Further more, it has to be kept in mind that depletion of CD4+ or C08+ T cell only partially inhibited the anti-tumor effects of Ad-injection (Fig. 4C ). This indicated that other antigen-non specific cellular (e.g. macrophages, killer dendritic cells) and non-cellular (e.g. growth-inhibiting or cytotoxic interleukins or cytokines) immune effector mechanisms might further contribute to Ad-mediated anti-tumor efficacy. Considering that >50% ofintra tumorally Ad-transduced cells were non-tumor cells (Fig. 3C) and that Ad-transduction significantly contributed to limiting the life span of all transduced cells (Fig. 4F) , a significant proportion of the anti-tumor effect could be the result of immune-mediated killing or functional inhibition of stroma cells (e.g. endothelial cells and fibroblasts). Although further work is needed to under stand by which immune mechanisms a tumor-localized Ad-vector inhibits tumor growth, we conclude that C04+ or C08+ T cells can be essential and that Ad-vector replication or transgene expression are not always essential for Ad-mediated anti-tumor efficacy.
In the sentinel LN we found that intratumoral Ad-injection further enhanced the natural induction not only of Ad-specific but also of neu-specific T cells (Fig. 3~) . Possible mechanisms for this phenomenon include that intratumoral Ad-injection increased expression ofco-stimulatory molecules on APCs inside the sentinel LN (Fig. S14) and also increased intratumoral apoptosis as a poten tial source for tumor-antigen that can be processed and presented by APCs (Fig. 3~) . It has been proposed that cross-presentation of tumor-antigens (derived from apoptotic tumor cells) is one main mechanism for the generation of tumor-specific T cell responses [51] and there has been another recent study that showed that viral infection (vesicular stomatitis virus) can synergize with the induction of tumor-specific immune responses inside the sentinel LN [52) . Since MMC cells did not spontaneously spread from the primary tumor to form metastasis inside the LN (unpublished observation), we were not able to functionally evaluate the poten tial of this response to prevent micrometastasis into the draining lymph nodes.
We discovered and characterized a vaccination approach that localized Ad-vector to the tumor. This induced T effector responses that were anti-tumor efficient in the presence of intra tumoral immunosuppression. Other analogous approaches that localize to the tumor certain surrogate antigens to which there is no central or peripheral tolerance might also prove successful.
